Subsequent biochemistry assays confirmed that DMF significantly increases GSH, cystathionine, and cysteine levels, along with moderately increased homocysteine levels (Fig
Many users identify this period as when they first feel confident the peptide is working meaningfully
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
It covers more pathways than CagriSema (which is missing GIP) but fewer than cag + retatrutide (which adds glucagon)
Interest in these peptides often comes from experimental findings linking them to signaling pathways involved in angiogenesis, cytoskeletal organization, and extracellular matrix remodeling